Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 586 • 2013 ACR/ARHP Annual Meeting
Blood Pressure Variability and Age-Related Blood Pressure Patterns In Systemic Lupus Erythematosus
George Stojan¹, Laurence S. Magder² and Michelle Petri³, ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Increased visit-to-visit blood pressure (BP) variability has been associated with an increased risk of all-cause mortality, stroke, left ventricular diastolic dysfunction, and cognitive impairment…
Abstract Number: 597 • 2013 ACR/ARHP Annual Meeting
Low Complement (C3), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus
Adnan Kiani¹, Armin Zadeh², Jens Vogel-Claussen¹, Joao Lima², Laurence S. Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: New technology (CTA) can measure non-calcified coronary plaque (NCP), which is highly unstable and prone to rupture. We quantified NCP in SLE and determined…
Abstract Number: 574 • 2013 ACR/ARHP Annual Meeting
Oral Candidiasis in Systemic Lupus Erythematosus
Monthida Fangtham, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Candida is the most common opportunistic fungal infection identified in SLE. In a previous autopsy study, 14 percent of deaths in SLE patients were…
Abstract Number: 2899 • 2013 ACR/ARHP Annual Meeting
Outcome Of Incidental Silent Strokes In Systemic Lupus Erythematosus
Jamal Mikdashi, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Silent strokes are brain infarcts that lack clinically overt stroke-like symptoms and fail to come to clinical attention. The prevalence of incidentally detected acute/subacute…
Abstract Number: 1897 • 2012 ACR/ARHP Annual Meeting
Pregnancy and Contraception in Adolescents and Teens with SLE: Are pediatric rheumatologists adequately Screening and Educating Their Patients?
Deirdre I. De Ranieri¹, Karen Onel², Linda Wagner-Weiner¹ and Melissa S. Tesher³, ¹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ²Pediatric Rheumatology, University of Chicago, Chicago, IL, ³Pediatric Rheum/MC 5044, University of Chicago, Chicago, IL
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is often complicated by both disease flares and risks to the fetus. It is important that young women with SLE be educated on both the…
Abstract Number: 943 • 2012 ACR/ARHP Annual Meeting
Impact of Systemic Lupus Erythematosus On Work Productivity and Income in the United States
Alan Oglesby¹, Ellen Sulcs², Siva Narayanan³, Mechele Lee² and Cindy Garris⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Healthcare Research, Harris Interactive Inc., Rochester, NY, ³Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ⁴US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disorder characterized by fluctuating periods of disease activity affecting multiple organ systems. This study was…
Abstract Number: 1795 • 2012 ACR/ARHP Annual Meeting
Correction for Basophil and Monocyte Frequencies Identifies Specific Gene Expression Differences Associated with SLE Disease Flare: Interim Report From the Bold (Biomarkers of Lupus Disease) Study
Mikhail G. Dozmorov¹, Nicolas Dominguez², Stan Kamp³, Cory Giles², Jonathan D. Wren⁴, Sudhakar T. Sridharan⁵, Joan T. Merrill³, Judith A. James⁶ and Joel M. Guthridge², ¹Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heterogeneity of clinical manifestations and pathogenic mechanisms has complicated treatment of SLE patients. The BOLD study allows evaluation of gene expression changes associated with…
Abstract Number: 944 • 2012 ACR/ARHP Annual Meeting
Job-Related Burden and Effort-Reward Imbalance in Patients with Systemic Lupus Erythematosus
Jutta G. Richter¹, Thomas Muth², Ralph Brinks¹, Tobias Koch³, Johannes Siegrist⁴, Nicole Hoffmann¹, Peter Angerer² and Matthias Schneider¹, ¹Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Institute for Occupational and Social Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴Department of Medical Sociology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Working life factors influence patients’ (life) satisfaction and well being. Effort at work is part of a social contract that reciprocates effort by adequate…
Abstract Number: 1710 • 2012 ACR/ARHP Annual Meeting
Increase in Vitamin D Improves Disease Activity and Systolic Blood Pressure in Systemic Lupus Erythematosus
Kayode J. Bello¹, Hong Fang², Laurence S. Magder³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Vitamin D deficiency has also been associated with different chronic conditions including cardiovascular diseases such as coronary artery disease, cardiac failure and hypertension. In…
Abstract Number: 932 • 2012 ACR/ARHP Annual Meeting
Medical Costs and Health Care Resource Use in Patients with Systemic Lupus Erythematosus in an Insured Population
Daniel Furst¹, Ann E. Clarke², Ancilla W. Fernandes³, Tim Bancroft⁴, Kavita Gajria³, Warren Greth⁵ and Serban R. Iorga⁴, ¹Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ²McGill University, Montreal, QC, Canada, ³MedImmune LLC, Gaithersburg, MD, ⁴OptumInsight, Eden Prairie, MN, ⁵Clinical Development, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that may affect multiple organ systems. The clinical manifestations of SLE are heterogeneous, and subjects…
Abstract Number: 1427 • 2012 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant?
Juan G. Ovalles-Bonilla¹, Julia Martínez-Barrio¹, Javier Lopez-Longo¹, Inmaculada de la Torre¹, Carlos Gonzalez Fernandez¹, María Montoro Álvarez¹, Francisco Aramburu¹, Carolina Marin¹, Lina Martinez-Estupiñan¹, Juan C. Nieto², Michelle Hinojosa¹, Natalia Bello¹, Indalecio Monteagudo¹ and Luis Carreño¹, ¹Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ²Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Classically, late onset Systemic Lupus Erythematosus (SLE) has been described as a milder variant of the disease. The objective of this study is to…
Abstract Number: 886 • 2012 ACR/ARHP Annual Meeting
Association Between Neutrophil Gene Signature and Disease Characteristics in Systemic Lupus Erythematosus Patients
Michelle Petri¹, Hong Fang¹, Jadwiga Bienkowska², Norm Allaire³, Jeff Browning⁴ and Susan Kalled³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Translational Medicine, Biogen Idec Inc., Cambridge, MA, ³Biogen Idec Inc., Cambridge, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: Neutrophils and neutrophil death (“netosis”) are now understood to play a role in the pathogenesis of SLE. A neutrophil gene signature exists in SLE,…
Abstract Number: 1412 • 2012 ACR/ARHP Annual Meeting
Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Adnan Kiani¹, Hong Fang¹, Tianfu Wu², Chandra Mohan³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ³Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. High levels of VCAM-1 have been…
Abstract Number: 843 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects
Erin Zoller¹, Leah C. Kottyan², Bahram Namjou¹, Samuel Vaughn¹, Miranda C. Marion³, Carl D. Langefeld⁴, Marta E. Alarcon-Riquelme⁵, Juan-Manuel Anaya⁶, Elizabeth E. Brown on behalf of PROFILE⁷, Sang-Cheol Bae⁸, Jeffrey C. Edberg⁹, Patrick M. Gaffney¹⁰, Diane L. Kamen¹¹, Robert P. Kimberly¹², Chaim O. Jacob¹³, Joan T. Merrill¹⁴, Kathy Moser Sivils¹⁵, Michelle Petri¹⁶, Rosalind Ramsey-Goldman¹⁷, John D. Reveille¹⁸, Anne M. Stevens¹⁹, Betty P. Tsao²⁰, Luis M. Vila²¹, Timothy J. Vyse²² and Kenneth M. Kaufman²³, ¹Division of Rheumatology and The Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁶School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹²Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ¹⁹Pediatrics, University of Washington, Seattle, WA, ²⁰Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²²Medical & Molecular Genetics, King's College London, London, United Kingdom, ²³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH
Background/Purpose: Powerful evidence suggests that Systemic lupus erythematous (SLE or lupus) autoimmunity is mediated by disregulation of the IRF5-NFκB signaling pathway. The interferon regulatory factor 5…
Abstract Number: 1387 • 2012 ACR/ARHP Annual Meeting
Hospitalizations and Reasons for Admission in a Clinical SLE Cohort
Alaa Dekis¹, Kenjey Chan¹, Christian A. Pineau², Evelyne Vinet³, Emil P. Nashi², Sasha Bernatsky⁴ and Ann E. Clarke⁴, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Center, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Data published from several countries have suggested that patients affected by systemic lupus erythematous (SLE) may have high annual hospitalization rates. However, there is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].